Brigitte Delemer1, Thierry Nguyen-Tan-Hon2, Romain Coriat3, Denis Smith4, Frank Schillo5, Isabelle Raingeard6, Iradj Sobhani7, Pierre-Luc Etienne8, Benedicte Decoudier1, Ségolène Bisot-Locard9, Alexandre Santos9, Gerald Raverot10, Guillaume Cadiot11. 1. Endocrinology, Diabetology and Nutrition Unit, University Hospital of Reims, Reims, France. 2. Medical Oncology Unit, University Hospital of Besançon, Besançon, France. 3. Gastroenterology Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris, Paris, France. 4. Digestive Oncology Unit, Haut-Levêque Hospital, University Hospital of Bordeaux, Pessac, France. 5. Diabetology Outpatient Unit, University Hospital of Besançon, Besançon, France. 6. Endocrinology, Diabetology and Nutrition Unit, University of Montpellier, Montpellier, France. 7. Gastroenterology Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. 8. Medical Oncology, CARIO-HPCA Center, Plérin, France. 9. Medical Oncology, Novartis, Rueil Malmaison, France. 10. Endocrine Department, Louis Pradel Hospital, Hospices Civils of Lyon, Lyon, France. 11. Hepatogastroenterology and Digestive Oncology Unit, University Hospital of Reims, Reims, France. gcadiot@chu-reims.fr.
Abstract
INTRODUCTION: The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR® (Novartis SAS) with a new diluent has been developed to facilitate its preparation and administration and to improve its use in practice. METHODS: We conducted an observational, cross-sectional and multicenter study in France whose main outcome was to compare nurses' satisfaction with the preparation and administration of both previous and new formulations of octreotide LAR. Secondary outcomes included assessment of patient satisfaction (quality of life and pain felt during the injection) and product tolerance. Data were collected at two time points (one for the first formulation group and one for the second formulation group) through paper questionnaires administered to physicians, patients and nurses including a visual analog scale (VAS) from 0 (unsatisfied) to 10 (very satisfied). RESULTS: Results showed that overall nurse satisfaction improved from 5.3 (95% CI 4.9-5.8) with the previous formulation to 7.5 (95% CI 7-7.9) with the new formulation (p < 0.0001). Regarding secondary outcomes, the simplicity of the injection increased (84% for the previous formulation and 94% for the new formulation) and the purge problem disappeared (36% for the previous formulation and 4% for the new formulation). CONCLUSION: The improvement due to the new formulation of Sandostatin LAR® was reported in terms of handling, ease of use and overall nurse satisfaction. The new formulation greatly reduced treatment administration problems associated with the previous formulation, while maintaining low injection site pain and an equivalent safety profile in both indications.
INTRODUCTION: The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR® (Novartis SAS) with a new diluent has been developed to facilitate its preparation and administration and to improve its use in practice. METHODS: We conducted an observational, cross-sectional and multicenter study in France whose main outcome was to compare nurses' satisfaction with the preparation and administration of both previous and new formulations of octreotide LAR. Secondary outcomes included assessment of patient satisfaction (quality of life and pain felt during the injection) and product tolerance. Data were collected at two time points (one for the first formulation group and one for the second formulation group) through paper questionnaires administered to physicians, patients and nurses including a visual analog scale (VAS) from 0 (unsatisfied) to 10 (very satisfied). RESULTS: Results showed that overall nurse satisfaction improved from 5.3 (95% CI 4.9-5.8) with the previous formulation to 7.5 (95% CI 7-7.9) with the new formulation (p < 0.0001). Regarding secondary outcomes, the simplicity of the injection increased (84% for the previous formulation and 94% for the new formulation) and the purge problem disappeared (36% for the previous formulation and 4% for the new formulation). CONCLUSION: The improvement due to the new formulation of Sandostatin LAR® was reported in terms of handling, ease of use and overall nurse satisfaction. The new formulation greatly reduced treatment administration problems associated with the previous formulation, while maintaining low injection site pain and an equivalent safety profile in both indications.
Entities:
Keywords:
Acromegaly; Neuroendocrine tumors; Nurses; Patients; Quality of life; Satisfaction; Somatostatin LAR
Authors: Philippe Chanson; Sylvie Salenave; Peter Kamenicky; Laure Cazabat; Jacques Young Journal: Best Pract Res Clin Endocrinol Metab Date: 2009-10 Impact factor: 4.690
Authors: W R Lenderking; C Zacker; L Katznelson; M L Vance; S Hossain; E Tafesse; A O Guacaneme; C L Pashos Journal: Value Health Date: 2000 Jul-Aug Impact factor: 5.725
Authors: Christian J Strasburger; Peter Vanuga; Juraj Payer; Marija Pfeifer; Vera Popovic; László Bajnok; Miklós Góth; Veˇra Olšovská; L'udmila Trejbalová; Janos Vadasz; Eyal Fima; Ronit Koren; Leanne Amitzi; Martin Bidlingmaier; Oren Hershkovitz; Gili Hart; Beverly M K Biller Journal: Eur J Endocrinol Date: 2016-12-08 Impact factor: 6.664
Authors: Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina Journal: Nat Rev Endocrinol Date: 2018-09 Impact factor: 43.330